Navigation Links
Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
Date:3/9/2009

d.yahoo.com/_ylt=Ai5xsLHy2xpMS7ltrCCS1wOuMncA/SIG=10tluocdp/**http%3A/www.isolagen.com/" target="_new">www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, without limitation, the Company's ability to complete any financings or enter into any strategic partnership or sell its ownership interest in Agera Laboratories, Inc. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
2. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
3. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
4. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
5. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
6. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
7. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
8. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
9. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
10. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a specialty ... innovative therapies for the treatment of acute pain, today ... the three and six months ended June 30, 2015. ... 23, 2015, the Committee for Medicinal Products for Human ... the management of acute moderate-to-severe post-operative pain in adult ...
(Date:8/3/2015)... Aug. 3, 2015 Diplomat Pharmacy, Inc. (NYSE: ... results for the quarter ended June 30, 2015. All comparisons, ... 2014. Second Quarter 2015 Highlights include: ... or $266 million , Total prescriptions dispensed of 234,000, ... versus 5.5% , Adjusted EBITDA of $22.7 million, an ...
(Date:8/3/2015)... , Aug. 3, 2015  LEO Pharma supports ... Administration (FDA) to include psoriasis as one of eight ... Development Initiative i .  Psoriasis is an autoimmune disease ... subsequent comorbidities, affecting 7.5 million people in the US ... Pharma,s ongoing commitment to supporting patients living with psoriasis, ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3
... ALLEGAN, Mich. , Jan. 27 Perrigo ... declared a quarterly dividend of $0.0625 per share, ... record on February 26, 2010 . , Perrigo Company ... distributes over-the-counter (OTC) and generic prescription pharmaceuticals, nutritional products, active ...
... , , , , RALEIGH, ... leading Clinical Research Organization, announces it has entered into a ... company, and its exclusive partner IBPC, a non-profit oncology research ... which collectively treat an estimated 140,000 new incidences of cancer ...
Cached Medicine Technology:PRA International Formalizes Partnership with Oncopartners and IBPC 2PRA International Formalizes Partnership with Oncopartners and IBPC 3PRA International Formalizes Partnership with Oncopartners and IBPC 4PRA International Formalizes Partnership with Oncopartners and IBPC 5
(Date:8/4/2015)... Hanover, MA (PRWEB) , ... August 04, 2015 , ... ... Brain Aneurysm Awareness on Sunday, September 20th at Oneida Shores Park in Brewerton, ... after suffering from a ruptured brain aneurysm at the young age of 59. Her ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA and the ... treating depression. Depression affects millions of Americans every single year. To help people ... enlighten viewers with the latest segment produced with the assistance of several top ...
(Date:8/4/2015)... DC (PRWEB) , ... August 04, 2015 , ... Following ... two new videos: The Benefits of Cath Lab Accreditation in an Academic Setting, and ... in an Academic Setting , taped during the 2015 Society for Cardiovascular Angiography ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... make the Isabel Symptom Checker available to all users of the KHIN personal ... check their symptoms in an easy, intuitive method, provides access to material on ...
(Date:8/3/2015)... ... 04, 2015 , ... While the pace of the economic recovery since the 2008 has been ... a growth trajectory for the last six years. Unemployment has dropped from a 2009 high ... 3.5 percent growth rate in 2014, the U.S. stock market is at an all time ...
Breaking Medicine News(10 mins):Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4
... -- A University of Michigan Health System laboratory study reveals ... could lead to a new treatment for those with sickle ... in this week,s early edition of the Proceedings of ... preventing the painful episodes and organ damage that are common ...
... Gordon HealthDay Reporter , TUESDAY, Nov. 1 (HealthDay ... their risk of developing cancer compared to the general population. ... cancer, according to new research. In any ... transplant is just 0.7 percent. And experts say the benefits ...
... Gardner HealthDay Reporter , TUESDAY, Nov. 1 ... disorder don,t appear to raise the risk of heart ... adults, new research shows. And if any ... Concerta does exist, the danger in absolute numbers would ...
... equation that is difficult to solve for most people, but ... transport can be an almost insurmountable task. A newly launched ... now enlisting the help of the senior citizens themselves to ... hoped that the results will lead to better urban planning. ...
... -- Women undergoing angioplasty, a procedure to unblock a clogged ... to new research. However, the study also shows ... an angioplasty than male patients. In conducting the study, ... Interventions , researchers analyzed information on almost 4,800 women and ...
... from Rhode Island Hospital examined how the perception of ... Through a web survey with embedded interventions, the researchers ... indicators of patient satisfaction, while staff reported changing or ... paper was published in the European Journal of ...
Cached Medicine News:Health News:Researchers reveal potential treatment for sickle cell disease 2Health News:Cancer Risk Doubles After Organ Transplant, Study Finds 2Health News:Cancer Risk Doubles After Organ Transplant, Study Finds 3Health News:Little Evidence of Heart Risks From ADHD Meds 2Health News:Little Evidence of Heart Risks From ADHD Meds 3Health News:Little Evidence of Heart Risks From ADHD Meds 4Health News:Senior citizens as co-researchers to improve urban planning 2Health News:Women No More Likely to Die After Angioplasty 2Health News:How staff perceptions of their roles impact patients experience in the emergency department 2Health News:How staff perceptions of their roles impact patients experience in the emergency department 3
... was developed to address hematology needs ... of use, low maintenance, closed-tube sampling, ... are features expected in the modern ... fast access to results, sophisticated data ...
Inquire...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: